US5472949A - N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same - Google Patents
N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same Download PDFInfo
- Publication number
- US5472949A US5472949A US08/167,392 US16739293A US5472949A US 5472949 A US5472949 A US 5472949A US 16739293 A US16739293 A US 16739293A US 5472949 A US5472949 A US 5472949A
- Authority
- US
- United States
- Prior art keywords
- deoxy
- radical
- cytidine
- fluoro
- fluorocytidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to N 4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives of formula (I), ##STR2## wherein R 1 is a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of the hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH 2 ) n --Y wherein Y is a cyclohexyl radical, a C 1 -C 4 alkoxy radical or a phenyl radical and n is an integer from 0 to 4; and when Y is a C 1 -C 4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R 2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,
- the compound is useful for treating tumors.
- the invention in another aspect, relates to a pharmaceutical composition including an effective amount of at least one compound of formula (I).
- the pharmaceutical composition has excellent pharmacokinetic profiles for treating tumors with high safety margin.
- the invention relates to a method of treating tumors comprising administering to a host in need of such treatment an effective amount of a compound of formula (I).
- the invention relates to a process for producing a N4-(substituted-oxycarbonyl)-5'-fluorocytidine derivatives which comprises reacting a compound of formula (II). ##STR3## wherein R 4 is a hydroxy-protecting radical, with a compound of formula (III)
- 5-fluorouracil 5-fluorouracil
- U.S. Pat. No. 4,966,891 discloses precursors of 5-FU which are improved in the above mentioned aspect of bioconversion efficiency and toxicities. They are converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by acylamidases, to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase, and then to 5-FU by pyrimidine nucleotide phosphorylase in vivo which is preferentially localized in the liver, small intestin and tumor tissues.
- 5'-DFCR 5'-deoxy-5-fluorocytidine
- 5'-DFUR 5'-deoxy-5-fluorouridine
- 5-FU pyrimidine nucleotide phosphorylase
- R 1 is a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH 2 ) n --Y wherein Y is a cyclohexyl radical, a C 1 -C 4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4, and when Y is C 1 -C 4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R 2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,
- a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven preferably is n-propyl, 1-isopropyl-2-methylpropyl, 1,1,2-trimethylpropyl, n-butyl, isobutyl, 2-ethylbutyl, 3,3-dimethylbutyl, n-pentyl, isopentyl, neopentyl, 2-propylpentyl, n-hexyl, 2-ethylhexyl, n-heptyl, allyl, 2-buten-1-yl, 3-buten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 3-hexen-1-yl, 4-hexen-1-yl, 5-hexen-1-yl, and the like.
- a radical of the formula --(CH 2 ) n --Y [in which n is an integer from 0 to 4, when Y is a cyclohexyl radical, or n is an integer from 2 to 4, when Y is a lower alkoxy radical having from 1 to 4 carbon atom(s) or a phenyl radical preferably is cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 2-methoxyethyl, 2-ethoxyethyl, 2-propoxyethyl, 3-methoxypropyl, 3-ethoxypropyl, 4-methoxybutyl, 4-ethoxybutyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, and the like.
- R 1 is n-propyl, n-butyl, n-pentyl, isopentyl, neopentyl, 3,3-dimethylbutyl, n-hexyl, 2-ethylbutyl, phenylethyl, or cyclohexylmethyl.
- a radical easily hydrolyzable under physiological condition preferably denotes acetyl, propionyl, benzoyl, toluoyl, ⁇ -alanyl, valyl, and the like.
- N 4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention are:
- N 4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention are:
- N 4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives hereinafter referred to as N 4 -(substituted-oxycarbonyl)-5'-DFCR) of formula (I) have selectively im pharmacokinetic profiles in monkeys, that is, 4 to 7 times higher maximum concentration (C max ) of 5'-DFUR and 4 times larger higher area under the curve (AUC) of 5'-DFUR in blood than the other compounds, and less intestinal toxicity.
- N 4 -(substituted-oxycarbonyl)-5'-DFCRs of formula (I) as well as their hydrates or solvates can be prepared by a reaction of a compound of formula (II), ##STR5## wherein R 4 is a hydroxy-protecting radical such as acetyl, benzoyl, trimethylsilyl, tert-butyldimethylsilyl, and the like,
- R 1 is the same as defined above,
- the compounds of formula (II) can be prepared by 2',3'-di-O-acylation or silylation of 5'-deoxy-5-fluorocytidine [J. Med. Chem., 22, 1330 (1979)]as described in U.S. Pat. No. 4,966,891 or by direct coupling of 5-fluorocytosine with 1,2,3-tri-O-acetyl-5-deoxyribofuranose according to the procedure similar to that described in Synthesis, 748 (1981).
- the reaction of the compound of formula (II) with the compound of formula (III) can be carried out in a solvent such as pyridine, dioxane, tetrahydrofuran, acetonitrile, chloroform, dichloromethane and the like in the presence of acid acceptor such as triethylamine, pyridine, picoline, 4-(N,N-dimethylamino)pyridine, lutidine and the like.
- the reaction can be carried out at a temperature between 0° and 30° C.
- the protecting radical may, if necessary, be removed after the reaction by the procedures known to those skilled in the art [Protective Groups in Organic Synthesis, John Wiley & Sons, New York, Can. J. Chem., 49, 493 (1971) and U.S. Pat. No. 4,966,891], for example by basic or acidic hydrolysis.
- the compounds of formula (I) can exist as unsolvated as well as solvated forms, including hydrated forms.
- the hydration can be effected in the course of the manufacturing process or can occur gradually as a result of hygroscopic properties of an initially anhydrous product.
- Solyates with pharmaceutically acceptable solvents such as ethanol can be obtained during, for example, crystallization.
- N 4 -(Substituted-oxycarobonyl)-5'-DFCR derivatives of formula (I) as well as hydrates or solyates thereof prepared by the above process exhibit activity against human colon cancer CXF280 and gastric cancer GXF97 xenografts, mouse colon 26 carcinoma, mouse Lewis lung carcinoma, and the like in mice over a very wide range of dosages both orally and parenterally and are useful as antitumor agents. They are efficiently converted to 5'-DFCR by an acylamidase isozyme, to 5'-DFUR by cytidine deaminase and then to the active metabolite 5-FU by pyrimidine nucleoside phosphorylase.
- the invention further relates to a pharmaceutical composition for the treatment of tumors.
- the pharmaceutical composition comprises an effective amount of one or more compounds of formula (I).
- the N 4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention can be administered orally or non-orally to hosts by various conventional administration methods. Moreover, the N 4 -(substituted-oxycarbonyl)-5'-DFCRs according to the invention are used singly or formulated with a compatible pharmaceutical carrier material.
- This carrier material can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral administration such as, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene-glycols or petroleum jelly.
- the pharmaceutical composition can be made up in a solid form, for example, as tablets, dragees, enteric coating tablets, granulars, enteric coating granulars, suppositories, capsules or enteric capsules, in a semi-solid form, for example, as salves, or in a liquid form, for example, as solutions, suspensions or emulsions.
- the pharmaceutical composition may be sterilized and/or may contain further adjuvants such as preserving, stabilizing, setting or emulsifying agents, flavor-improving agents, salts for variation of the osmotic pressure or substances acting as buffers.
- the pharmaceutical composition can be prepared in a conventional manner.
- the N 4 -(substituted-oxycarbonyl)-5'-DFCRs according to the present invention can be used alone or as mixtures of two or more different N 4 -(substituted-oxycarbonyl)-5'-DFCRs and the amount of the N 4 -(substituted-oxycarbonyl)-5'-DFCRs is about 0.1 to 99.5%, preferably 0.5 to 95%, based on the weight of the pharmaceutical composition.
- composition according to the present invention may be formulated in a combination with other conventional antitumor agent.
- the invention also relates to a method of treating tumors comprising administering to a host in need of such treatment an effective amount of at least one compound of formula (I).
- N 4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention were incubated with crude extracts of monkey and human liver in the presence of an inhibitor of cytidine deaminase, tetrahydrouridine (0.4 mM) at 37° C. for 60 min. Thereafter, the product 5'-DFCR was separated by HPLC and the enzyme susceptibility was calculated from the amount of the product.
- Table 1 shows, the compounds of formula (I) were highly susceptible to the human liver acylamidase, suggesting that they are efficiently biotransformed to 5'-DFCR in human.
- the compounds of formula (I) were orally administered into groups of 2 to 5 cynomolgous monkeys (3-4 kg). At various times after the administration, plasma was taken for determination of blood concentrations of intact molecules and their active metabolite 5'-DFUR.
- CXF280 tumor (about 2 ⁇ 2 mm piece) was implanted subcutaneously into BALB/c nu/nu mice (21-22 g) on day 0.
- tumor volume became 100 mm 3 on day around 14, the compounds of the invention were orally administered daily for 3 weeks.
- tumor volume was calculated.
- V 0 volume of tumor before treatment was started
- T volume of the tumors from the treated group
- C volume of the tumor from the control group.
- Antitumor activity of a representative compound (Example 13), of the present invention was measured as follows. Mice (CDF 1 ) were subcutaneously inoculated with colon 26 carcinoma (10 6 cells) on day 0. The compound was administered daily for 7 times from day 21 when the animals became cachectic. One day after the last treatment, tumor weight gain, carcass weight gain, adipose tissue weight, concentrations of glucose and the acute phase reactant IAP (immunosuppressive acidic protein) in the serum were measured. As Table 4 shows, mice treated with vehicle were abnormal in cachexia parameters such as adipose tissue weight, serum glucose and IAP levels, whereas treatment with the compound of Example 13 suppressed tumor growth and improved cachexia.
- IAP immunosuppressive acidic protein
- the toxicity (LD 50 ) of the representative compounds (Example 13,14, and 17) of the present invention was examined by oral administration daily for 21 days in mice.
- the representative LD 50 values obtained from the experiments were more than 500 mg/kg/day.
- a dosage per day to a patient of the N 4 -(substituted-oxycarbonyl)-5'-DFCRs of the present invention may be varied depending upon his weight and state to be remedied, but generally is in the range of 0.5 to 500 mg per 1 kg of weight, preferably about 2 to 200 mg.
- the compound of the invention can be expected to have 3-5 times higher activity than those of the compounds disclosed in U.S. Pat. No. 4,966,891 in humans, when taking into consideration of the data of C max and AUC of 5'-DFUR after oral administration of the present compounds in monkeys. From the same reason, the compounds of the present invention can be expected to show sufficient activity at the 3-5 times lower dosage than those of the compounds of U.S. Pat. No. 4,966,891.
- the present invention can provide a pharmaceutical composition for treating tumors with high safety margin.
- 5'-Deoxy-5-fluorocytidine 50 mg was dissolved in dry pyridine (1.3 ml). To the solution was added acetic anhydride (39 ml) with stirring at 0° C. The reaction mixture was stirred for 3 hours at 0° C. After removal of the solvent under reduced pressure, the residue was partitioned between ethyl acetate and ice cooled water. The ethyl acetate layer was dried over magnesium sulfate and concentrated under reduced pressure.
- Example 9 The following compounds were obtained according to a manner analogous to that of Example 1.
- the compound of Example 9 was prepared from the known 2',3'-di-O-benzoyl-5'-deoxy-5-fluorocytidine (U.S. Pat. No. 4,966,891) by the similar manner to that of Example 1.
- 5'-Deoxy-5-fluorocytidine (2.5 g) was dissolved in dry pyridine (20 ml). To the mixture, trimethylsilyl chloride (3.4 ml) was added dropwise at 0° C., and stirred for 30 min at room temperature. To the reaction mixture, cyclohexyl chloroformate (2.0 ml) was added in one portion at 0° C. After stirring of the mixture for 1 hour at room temperature, pyridine was evaporated under reduced pressure. The residue was then partitioned between saturated aqueous NaHCO 3 and ether. The organic layer was washed with brine, dried over anhydrous MgSO 4 and concentrated under reduced pressure.
- Dry parenteral dosage forms were manufactured in a manner known per se:
- the above dry dosage forms were reconstituted before use by adding a suitable sterile aqueous solvent such as water for injection or isotonic sodium chloride or 5% dextrose for parenteral administration.
- a suitable sterile aqueous solvent such as water for injection or isotonic sodium chloride or 5% dextrose for parenteral administration.
Abstract
The invention relates to N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives which are useful as an agent for treating tumors, pharmaceutical compositions including the same, a method of treating tumors and a method of preparing N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives for treating tumors.
Compounds of formula (I), ##STR1## wherein R1 is a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH2)n--Y wherein Y is a cyclohexyl radical, a C1 -C4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4, and when Y is C1 -C4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,
or a hydrate or solvate thereof. Compounds of formula (I) are useful in the treatment of tumors.
Description
The invention relates to N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives of formula (I), ##STR2## wherein R1 is a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of the hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH2)n --Y wherein Y is a cyclohexyl radical, a C1 -C4 alkoxy radical or a phenyl radical and n is an integer from 0 to 4; and when Y is a C1 -C4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,
or a hydrate or solvate thereof. The compound is useful for treating tumors.
In another aspect, the invention relates to a pharmaceutical composition including an effective amount of at least one compound of formula (I). The pharmaceutical composition has excellent pharmacokinetic profiles for treating tumors with high safety margin.
In yet a further aspect, the invention relates to a method of treating tumors comprising administering to a host in need of such treatment an effective amount of a compound of formula (I).
In yet another aspect, the invention relates to a process for producing a N4-(substituted-oxycarbonyl)-5'-fluorocytidine derivatives which comprises reacting a compound of formula (II). ##STR3## wherein R4 is a hydroxy-protecting radical, with a compound of formula (III)
R.sup.1 OCOCl (III)
and, optionally, removing R4.
It is known that many precursors of 5-fluorouracil (5-FU) are useful as antitumor agents, but in general their bioconversion efficiency is still insufficient for the treatment of patients suffering from tumors. Further they cause intestinal toxicities and immunosuppressive toxicities, which are their major and dose limiting toxicities, respectively.
U.S. Pat. No. 4,966,891 discloses precursors of 5-FU which are improved in the above mentioned aspect of bioconversion efficiency and toxicities. They are converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by acylamidases, to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase, and then to 5-FU by pyrimidine nucleotide phosphorylase in vivo which is preferentially localized in the liver, small intestin and tumor tissues.
The invention relates to compounds of formula (I), ##STR4## wherein R1 is a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH2)n --Y wherein Y is a cyclohexyl radical, a C1 -C4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4, and when Y is C1 -C4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,
or a hydrate or solvate thereof. Compounds of formula (I) are useful in the treatment of tumors.
In the above, the term a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven preferably is n-propyl, 1-isopropyl-2-methylpropyl, 1,1,2-trimethylpropyl, n-butyl, isobutyl, 2-ethylbutyl, 3,3-dimethylbutyl, n-pentyl, isopentyl, neopentyl, 2-propylpentyl, n-hexyl, 2-ethylhexyl, n-heptyl, allyl, 2-buten-1-yl, 3-buten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 3-hexen-1-yl, 4-hexen-1-yl, 5-hexen-1-yl, and the like.
The term a radical of the formula --(CH2)n --Y [in which n is an integer from 0 to 4, when Y is a cyclohexyl radical, or n is an integer from 2 to 4, when Y is a lower alkoxy radical having from 1 to 4 carbon atom(s) or a phenyl radical preferably is cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 2-methoxyethyl, 2-ethoxyethyl, 2-propoxyethyl, 3-methoxypropyl, 3-ethoxypropyl, 4-methoxybutyl, 4-ethoxybutyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, and the like.
Most preferably, R1 is n-propyl, n-butyl, n-pentyl, isopentyl, neopentyl, 3,3-dimethylbutyl, n-hexyl, 2-ethylbutyl, phenylethyl, or cyclohexylmethyl.
In the above, the term a radical easily hydrolyzable under physiological condition preferably denotes acetyl, propionyl, benzoyl, toluoyl, β-alanyl, valyl, and the like.
Preferred N4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention are:
5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine,
N 4 -(butoxycarbonyl)-5'-deoxy-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -(pentyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -(hexyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -(isopentyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -(neopentyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -[(1,1,2-trimethylpropoxy)carbonyl]cytidine,
5'-deoxy-N4 -[(3,3-dimethylbutoxy)carbonyl]-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -[(1-isopropyl-2-methylpropoxy)carbonyl]cytidine,
5'-deoxy-N4 -[(2-ethylbutoxy)carbonyl]-5-fluorocytidine,
N4 -[(cyclohexylmethoxy)carbonyl]-5'-deoxy-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -[(2-phenylethoxy)carbonyl]cytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine,
2',3'-di-acetyl-N4 -(butoxycarbonyl)-5'-deoxy-5-fluorocytidine,
2',3'-di-benzoyl-N4 -(butoxycarbonyl)-5'-deoxy-5-fluorocytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(pentyloxycarbonyl)cytidine,
2',3'-di-acetyl-5'-deoxy-5-fluoro-N4 -(isopentyloxycarbonyl)cytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(hexyloxycarbonyl)-cytidine,
2',3'-di-O-acetyl-5'-deoxy-N4 -[(2-ethylbutyl)oxycarbonyl]-5 -fluorocytidine,
2',3'-di-O-acetyl-N4 -[(cyclohexylmethoxy)carbonyl]-5'-deoxy-5-fluorocytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -[(2-phenylethoxy)carbonyl]cytidine,
5'-deoxy-5-fluoro-N4 -(isobutoxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -[(2-propylpentyl)oxycarbonyl]cytidine,
5'-deoxy-N4 -[(2-ethylhexyl)oxycarbonyl]-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -(heptyloxycarbonyl)cytidine,
N4 -[(2-cyclohexylethoxy)carbonyl]-5'-deoxy-5-fluorocytidine,
N4 -[(3-cyclohexylpropyl)oxycarbonyl]-5'-deoxy-5-fluorocytidine,
N4 -(cyclohexyloxycarbonyl)-5'-deoxy-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -[(3-phenylpropyl)oxycarbonyl]cytidine, and
5'-deoxy-5-fluoro-N4 -[(2-methoxyethoxy)carbonyl]cytidine.
and their hydrates or solyates, and the like.
Among the above compounds, particularly preferred N4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention are:
5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -(isopentyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -(hexyloxycarbonyl)cytidine,
5'-deoxy-N4 -[(2-ethylbutyl)oxycarbonyl]-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -(neopentyloxycarbonyl)cytidine,
5'-deoxy-N4 -[(3,3 -dimethylbutoxy)carbonyl]-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -[(2-phenylethoxy)carbonyl]cytidine,
N4 -[(cyclohexylmethoxy)carbonyl]-5'-deoxy-5-fluorocytidine, specially
N4 -(butoxycarbonyl)-5'-deoxy-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -(pentyloxycarbonyl)cytidine, and their hydrates or solvates, and the like.
Studies on the pharmacokinetic profiles of the precursors of 5-FU, particularly of N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives, showed that certain specific precursors are selectively converted into 5'-DFCR by an acylamidase isozyme that is preferentially located at the liver but not the other organs of humans, and exhibited more improved pharmacokinetic profiles than the other compounds tested. Further studies based on the above findings enabled identification that the specific N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives (hereinafter referred to as N4 -(substituted-oxycarbonyl)-5'-DFCR) of formula (I) have selectively im pharmacokinetic profiles in monkeys, that is, 4 to 7 times higher maximum concentration (Cmax) of 5'-DFUR and 4 times larger higher area under the curve (AUC) of 5'-DFUR in blood than the other compounds, and less intestinal toxicity.
The N4 -(substituted-oxycarbonyl)-5'-DFCRs of formula (I) as well as their hydrates or solvates can be prepared by a reaction of a compound of formula (II), ##STR5## wherein R4 is a hydroxy-protecting radical such as acetyl, benzoyl, trimethylsilyl, tert-butyldimethylsilyl, and the like,
with a compound of formula (III),
R.sup.1 OCOCl (III)
wherein R1 is the same as defined above,
followed, if necessary, by removal of a protecting radical.
The compounds of formula (II) can be prepared by 2',3'-di-O-acylation or silylation of 5'-deoxy-5-fluorocytidine [J. Med. Chem., 22, 1330 (1979)]as described in U.S. Pat. No. 4,966,891 or by direct coupling of 5-fluorocytosine with 1,2,3-tri-O-acetyl-5-deoxyribofuranose according to the procedure similar to that described in Synthesis, 748 (1981).
The reaction of the compound of formula (II) with the compound of formula (III) can be carried out in a solvent such as pyridine, dioxane, tetrahydrofuran, acetonitrile, chloroform, dichloromethane and the like in the presence of acid acceptor such as triethylamine, pyridine, picoline, 4-(N,N-dimethylamino)pyridine, lutidine and the like. The reaction can be carried out at a temperature between 0° and 30° C.
The protecting radical may, if necessary, be removed after the reaction by the procedures known to those skilled in the art [Protective Groups in Organic Synthesis, John Wiley & Sons, New York, Can. J. Chem., 49, 493 (1971) and U.S. Pat. No. 4,966,891], for example by basic or acidic hydrolysis.
The compounds of formula (I) can exist as unsolvated as well as solvated forms, including hydrated forms. The hydration can be effected in the course of the manufacturing process or can occur gradually as a result of hygroscopic properties of an initially anhydrous product. Solyates with pharmaceutically acceptable solvents such as ethanol can be obtained during, for example, crystallization.
N4 -(Substituted-oxycarobonyl)-5'-DFCR derivatives of formula (I) as well as hydrates or solyates thereof prepared by the above process exhibit activity against human colon cancer CXF280 and gastric cancer GXF97 xenografts, mouse colon 26 carcinoma, mouse Lewis lung carcinoma, and the like in mice over a very wide range of dosages both orally and parenterally and are useful as antitumor agents. They are efficiently converted to 5'-DFCR by an acylamidase isozyme, to 5'-DFUR by cytidine deaminase and then to the active metabolite 5-FU by pyrimidine nucleoside phosphorylase.
The invention further relates to a pharmaceutical composition for the treatment of tumors. The pharmaceutical composition comprises an effective amount of one or more compounds of formula (I).
The N4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention can be administered orally or non-orally to hosts by various conventional administration methods. Moreover, the N4 -(substituted-oxycarbonyl)-5'-DFCRs according to the invention are used singly or formulated with a compatible pharmaceutical carrier material. This carrier material can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral administration such as, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene-glycols or petroleum jelly. The pharmaceutical composition can be made up in a solid form, for example, as tablets, dragees, enteric coating tablets, granulars, enteric coating granulars, suppositories, capsules or enteric capsules, in a semi-solid form, for example, as salves, or in a liquid form, for example, as solutions, suspensions or emulsions. The pharmaceutical composition may be sterilized and/or may contain further adjuvants such as preserving, stabilizing, setting or emulsifying agents, flavor-improving agents, salts for variation of the osmotic pressure or substances acting as buffers. The pharmaceutical composition can be prepared in a conventional manner.
The N4 -(substituted-oxycarbonyl)-5'-DFCRs according to the present invention can be used alone or as mixtures of two or more different N4 -(substituted-oxycarbonyl)-5'-DFCRs and the amount of the N4 -(substituted-oxycarbonyl)-5'-DFCRs is about 0.1 to 99.5%, preferably 0.5 to 95%, based on the weight of the pharmaceutical composition.
The pharmaceutical composition according to the present invention may be formulated in a combination with other conventional antitumor agent.
The invention also relates to a method of treating tumors comprising administering to a host in need of such treatment an effective amount of at least one compound of formula (I).
Susceptibility to acylamidase of the N4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention and their pharmacokinetic profil monkey are shown below:
1. Susceptibility to human and monkey acylamidases
The N4 -(substituted-oxycarbonyl)-5'-DFCRs of the invention were incubated with crude extracts of monkey and human liver in the presence of an inhibitor of cytidine deaminase, tetrahydrouridine (0.4 mM) at 37° C. for 60 min. Thereafter, the product 5'-DFCR was separated by HPLC and the enzyme susceptibility was calculated from the amount of the product. As Table 1 shows, the compounds of formula (I) were highly susceptible to the human liver acylamidase, suggesting that they are efficiently biotransformed to 5'-DFCR in human.
TABLE 1
______________________________________
Susceptibility to monkey and human acylamidase in the liver
Acylamidase activity (nmol/mg
protein/hr)
Compound Monkey Human
(Example No.) Liver Liver
______________________________________
11 20 71
12 29 190
13 47 220
14 32 74
15 23 210
16 33 210
17 22 160
20 19 320
21 26 82
22 43 110
24 18 64
25 <13 160
26 20 560
27 59 110
28 25 52
29 22 50
______________________________________
2. Pharmacokinetic profiles in monkeys
The compounds of formula (I) were orally administered into groups of 2 to 5 cynomolgous monkeys (3-4 kg). At various times after the administration, plasma was taken for determination of blood concentrations of intact molecules and their active metabolite 5'-DFUR.
Metabolites in the plasma were separated by HPLC and their concentrations were calculated. As Table 2 shows, the compounds of the present invention gave high levels in Cmax and AUC of the active metabolite 5'-DFUR in the plasma. These results indicate that the compounds of the invention can be effectively utilized for the treatment of various tumors in human beings.
TABLE 2
______________________________________
Pharmacokinetic Profiles in Monkeys
Plasma
5'-DFUR
Compound Cmax AUC
(Example No.) (μg/ml)
(μg · hr/ml)
______________________________________
10 1.44 2.03
11 1.57 2.06
12 2.10 2.90
13 1.50 1.96
14 1.80 2.40
15 2.60 2.89
16 1.40 2.52
17 1.65 2.66
28 1.00 1.40
29 2.00 2.09
______________________________________
The antitumor activities of the compounds of the invention are shown as follows:
3. Antitumor testing against human colon cancer xenograft CXF280
CXF280 tumor (about 2×2 mm piece) was implanted subcutaneously into BALB/c nu/nu mice (21-22 g) on day 0. When tumor volume became 100 mm3 on day around 14, the compounds of the invention were orally administered daily for 3 weeks. At one day after the last treatment, tumor volume was calculated.
TABLE 3
______________________________________
Antitumor Effects of Fluorinated Pyrimidines in BALB/c
nu/nu Mice Bearing CXF280 Human Colon Carcinoma
Compound Dose × 21
% Growth Fecal
(Example No.)
(mmol/kg/day)
inhibition
observation*
______________________________________
Exp. 1
Vehicle -- N
12 0.13 68
0.3 69
0.67 86
1.0 86
1.5 96 N
13 0.13 59
0.3 66
0.67 79
1.0 91
1.5 94 N
24 0.13 37
0.3 64
0.67 75
1.0 83
1.5 89 N
Reference
compound
5-FU 0.089 28 N
0.13 59 N
0.2 79 L
Exp. 2
Vehicle -- N
10 0.13 39
0.3 56
0.67 75
1.5 86
2.25 93 N
11 0.13 46
0.3 72
0.67 84
1.5 95
2.25 100 N
14 0.13 68
0.3 68
0.67 85
1.5 94 N
2.25 100 N
27 0.13 26
0.3 72
0.67 84
1.5 94 N
2.25 103 N
Reference
compound
5-FU 0.089 NE N
0.13 20 N
0.2 58 L
______________________________________
NE: Not Effective,
*Fecal observation (N: normal feces, L: loose passage)
The percent inhibition of tumor growth given in Table 3 above was calculated from the formula:
% Inhibition ={1-(T-V.sub.0)/(C-V.sub.0)}×100
V0 =volume of tumor before treatment was started, T=volume of the tumors from the treated group, C=volume of the tumor from the control group.
As Table 3 shows, the compounds provided in the present invention were safely administered without causing intestinal toxicity and were much more effective than 5-FU.
4. Antitumor and anticachexia activity against mouse colon 26 carcinoma
Antitumor activity of a representative compound (Example 13), of the present invention, was measured as follows. Mice (CDF1) were subcutaneously inoculated with colon 26 carcinoma (106 cells) on day 0. The compound was administered daily for 7 times from day 21 when the animals became cachectic. One day after the last treatment, tumor weight gain, carcass weight gain, adipose tissue weight, concentrations of glucose and the acute phase reactant IAP (immunosuppressive acidic protein) in the serum were measured. As Table 4 shows, mice treated with vehicle were abnormal in cachexia parameters such as adipose tissue weight, serum glucose and IAP levels, whereas treatment with the compound of Example 13 suppressed tumor growth and improved cachexia.
TABLE 4
______________________________________
Improvement of Tumor Cachexia with Fluorinated Pyrimidines
in Mice Bearing Colon 26 Adenocarcinoma
Com- Dose ×
Tumor Carcass
Adipose
Serum
pound 7 (mmol/ wt. wt. tissue glucose
Ser-
(Example
kg) change change wt. (mg/ um
No.) (μg/ml)
(g) (g) (mg) dl) IAP
______________________________________
Vehicle 1.65 -1.5 11 91 1167
13 0.125 1.24 1.6* 22* 118* 1195
0.25 0.91 3.4* 42* 120* 1020
0.5 0.79* 4.2* 63* 147* 805*
1 0.006 5.6* 85* 127* 795*
______________________________________
*P < 0.05 versus corresponding value of vehicle group
The toxicity (LD50) of the representative compounds (Example 13,14, and 17) of the present invention was examined by oral administration daily for 21 days in mice. The representative LD50 values obtained from the experiments were more than 500 mg/kg/day.
A dosage per day to a patient of the N4 -(substituted-oxycarbonyl)-5'-DFCRs of the present invention may be varied depending upon his weight and state to be remedied, but generally is in the range of 0.5 to 500 mg per 1 kg of weight, preferably about 2 to 200 mg. It should be noted that the compound of the invention can be expected to have 3-5 times higher activity than those of the compounds disclosed in U.S. Pat. No. 4,966,891 in humans, when taking into consideration of the data of Cmax and AUC of 5'-DFUR after oral administration of the present compounds in monkeys. From the same reason, the compounds of the present invention can be expected to show sufficient activity at the 3-5 times lower dosage than those of the compounds of U.S. Pat. No. 4,966,891. The present invention can provide a pharmaceutical composition for treating tumors with high safety margin.
Reference example: Preparation of starting material
Preparation of 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine
(a) From 5'-deoxy-5-fluorocytidine
5'-Deoxy-5-fluorocytidine (50 mg) was dissolved in dry pyridine (1.3 ml). To the solution was added acetic anhydride (39 ml) with stirring at 0° C. The reaction mixture was stirred for 3 hours at 0° C. After removal of the solvent under reduced pressure, the residue was partitioned between ethyl acetate and ice cooled water. The ethyl acetate layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol=9/1 as an eluent) followed by recrystallization from isopropanol to give 37 mg of 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine: 191.5°-193° C., FAB-MS m/z 330 (MH+).
(b) From 5-fluorocytosine and 1,2,3-tri-O-acetyl-5-deoxy-β-D-ribofuranose
A solution of sodium iodide (3.6 g) and chlorotrimethylsilane (794 ml) in dry acetonitrile (15 ml) was stirred with molecular sieves 4A (200 mg) at 0° C. for 5 minutes (colorless sodium chloride deposited during stirring). 1,2,3-Tri-O-acetyl-5-deoxy-β-D-ribofuranose (2.0 g) was added and the mixture was stirred at 0° C. for 30 min. Then, a solution of the trimethylsilylated 5-fluorocytosine, freshly prepared from 5-fluorocytosine (1.12 g), in dry acetonitrile (5 ml) was added at 0° C. and stirring was continued for 3 h at room temperature. The mixture was filtered, the filtrate was concentrated in vacuo, and the residue was partitioned between dichloromethane and saturated aq. sodium bicarbonate solution. The aqueous layer was extracted with CH2 Cl2 /MeOH (10:1). The combined organic layers were dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was purified by silica gel chromatography using CH2 Cl2 /MeOH (15:1) as an eluent, followed by recrystallization from isopropanol to give 1.24 g of 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine.
Preparation of 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine
To a solution of 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine (2 g) in CH2 Cl2 (15 ml) and dry pyridine (983 ml) was added dropwise n-propyl chloroformate (957 ml) with stirring and cooling on ice bath. After stirring for 30 min at room temperature, the mixture was evaporated to dryness under reduced pressure. The residue was partitioned between ether and saturated aqueous solution of sodium bicarbonate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered.
The filtrate was evaporated to give 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine (2.5 g) :EI-MS m/z 415(M+); 1 H-NMR(d6 -DMSO) δ0.92 (3H, t, J=7.3 Hz), 1.37 (3H, d, J=6.3 Hz), 1.63 (2H, sex, J=7.3 Hz), 4.06-4.14 (3H, m), 5.11 (1H, t, J=6.3 Hz), 5.47 (1H, d.d., J=4.6 & 6.3 Hz), 5.81 (1H, d, J=4.6 Hz), 8.31 (1H, br. s), 10.63 (1H, br. s)
The following compounds were obtained according to a manner analogous to that of Example 1. The compound of Example 9 was prepared from the known 2',3'-di-O-benzoyl-5'-deoxy-5-fluorocytidine (U.S. Pat. No. 4,966,891) by the similar manner to that of Example 1.
__________________________________________________________________________
.sup.1 H-NMR FAB-MS
Example No.
R.sup.1
R.sup.2
(in solvent 1 or 2) (m/z)
__________________________________________________________________________
2 n-butyl
acetyl
δ(1): 0.87(3H, t, J=7.3Hz), 1.36(5H, m),
1.59(2H, m), 430(MH.sup.+)
2.05(3H, s), 2.07(3H, s), 4.12(3H, m), 5.11(1H,
br.t), 5.47(1H, br, t), 5.81(1H, d, J=4.3Hz), 8.34
(1H, br.s), 10.60(1H, br.s)
3 n-pentyl
acetyl
δ(1): 0.88(3H, t, J=7.3Hz), 1.31(5H, m),
444(MH+)
(3H, d, J=6.3Hz), 1.61(1H, m), 2.06(3H, s),
2.07(3H, s), 4.07-4.14(3H, m), 5.11(1H, t, J=6.3Hz),
5.47(1H, d.d, J=6.3 & 4.6Hz), 5.80(1H, d, J=4.6Hz),
8.28(1H, br.s), 10.63(1H, br.s)
4 n-hexyl
acetyl
δ(1): 0.87(3H, t, J=6.9Hz), 1.30(6H, m),
1.36(3H, d, 458(MH+)
J=6.3Hz), 1.59(2H, m), 2.06(3H, s), 2.07(3H, s),
4.07-4.14(3H, m), 5.11(1H, t, J=6.3Hz), 5.45(1H, d.d,
J=6.3 & 4.6Hz), 5.80(1H, d, J=4.6Hz), 8.28(1H, br s),
10.63(1H, br.s)
5 isopentyl
acetyl
δ(1): 0.90(6H, d, J= 6.9Hz), 1.36(3H, d,
J=6.3Hz), 1.51 444(MH+)
(2H, q, J=6.9Hz), 1.68(1H, m), 2.06(3H, s), 2.07
(3H, s), 4.09-4.20(3H, m), 5.11(1H, t, J=6.3Hz),
5.46(1H, d.d, J=6.3 & 4.3Hz), 5.80(1H, d, J=4.3Hz),
8.28(1H, br.s), 10.63(1H, br.s)
6 2-ethylbutyl
acetyl
δ(1): 0.87(6H, t, J=7.3Hz), 1.23-1.45(7H,
458(MH+)
1.51(1H, m), 2.06(3H, s), 2.07(3H, s), 4.04
(2H, br.d), 4.12(1H, t, J=6.3Hz), 5.11(1H, t,
J=6.3Hz), 5.46(1H, d.d., J=6.3 & 4.6Hz), 5.81
(d, J=4.6Hz), 8.32(1H, br.s), 10.61(1H, br.s)
7 cyclohexyl-
acetyl
δ(1): 1.00(2H, m), 1.11-1.29(4H, m),
470(MH+)
methyl d, J=6.3Hz), 1.57-1.77(5H, m), 2.06(3H, s), 2.07
(3H, s), 3.92(2H, br.s), 4.12(1H, m), 5.11(1H,
t, J=6.3Hz), 5.46(1H, d.d, J=6.3 & 4.0Hz), 5.81(1H,
d, J=4.0Hz), 8.33(1H, br.s), 10.61(1H, br.s)
8 phenethyl
acetyl
δ(1): 1.36(3H, d, J=6.3Hz), 2.06(3H, s),
478(MH+)
(3H, s), 2.94(2H, t, J=6.8Hz), 4.12(1H, m), 4.32
(2H, br.t), 5.11(1H, t, J=6.3Hz), 5.46(1H, d.d,
J=6.3 & 4.3Hz), 5.81(1H, d, J=4.3Hz), 7.16-7.37
(5H, m), 8.32(1H, br.s), 10.67(1H, br.s)
9 n-butyl
benzoyl
δ(2): 0.95(3H, t, J=7.3Hz), 1.42(2H, m)
554(MH+)
(3H, d, J=6.3Hz), 1.68(2H, m), 4.16(2H, br.s),
4.52(1H, d.q, J=5.8 & 6.3Hz), 5.40(1H, t, J=5.8Hz)
5.65(1H, d.d, J=4.6 & 5.8Hz), 6.16(1H, d, J=4.6Hz),
7.35-7.98(11H, m), 11.9(1H, br.s)
__________________________________________________________________________
NMR: solvent 1 = d.sub.6DMSO, Solvent 2 = CDCl.sub.3
Preparation of 5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine
To a solution of 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine (2.5 g) in CH2 Cl2 (17 ml) was added dropwise 1N NaOH (17 ml) with stirring and cooling with ice bath. After stirring for 1 hr at 0° C., MeOH (0.9 ml) was added to the mixture. And pH of the reaction mixture was adjusted to 6 by the addition of concentrated HCl and partitioned. The aqueous layer was extracted with a mixed solvent of CH2 Cl2 /MeOH(95/5) successively (40 ml×10). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The solution was evaporated, and the residue was crystallized from ethyl acetate to give 5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine as colorless crystals (1.6 g, y. 79.8%): mp. 125°-126.5° C.; EI-MS m/z 331 (M+).
The following compounds were obtained according to a manner analogous to that of Example 10.
__________________________________________________________________________
Example Melting
Recrystallization
FAB-MS
No. R.sup.1
R.sup.2
point (°C.)
solvent m/z
__________________________________________________________________________
11 n-butyl
H 119-120
AcOEt 346(MH.sup.+)
12 n-pentyl
H 110-121
AcOEt EI 359(M.sup.+)
13 n-hexyl
H 114-116
AcOEt EI 373(M.sup.+)
14 isopentyl
H 119-120
AcOEt 360(MH.sup.+)
15 2-ethylbutyl
H amorphous*
-- 374(MH.sup.+)
16 cyclohexyl-
H 126-127
AcOEt 386(MH.sup.+)
methyl
17 phenethyl
H 144-145
AcOEt--MeOH
394(MH.sup.+)
18 allyl H 118.5-120
AcOEt 330(MH.sup.+)
__________________________________________________________________________
*.sup.1 HNMR(d.sub.6DMSO) of Example 15: δ 0.87(6H, t, J=7Hz),
1.25-1.45(7H, m), 1.53(1H, m), 3.68(1H, q., J=6 Hz), 3.89(1H, br. t,
J=6Hz), 4.02(2H, d, J=6Hz), 4.10(1H, m), 5.05(1H, d, J=6Hz), 5.4(1H, d,
J=6Hz), 5.67(1H, d, J=3Hz), 8.00(1H, br. s), 10.55 & 11.60 (total 1H, br.
s each).
Preparation of N4 -(cyclohexyloxycarbonyl)-5'-deoxy-5-fluorocytidine
5'-Deoxy-5-fluorocytidine (2.5 g) was dissolved in dry pyridine (20 ml). To the mixture, trimethylsilyl chloride (3.4 ml) was added dropwise at 0° C., and stirred for 30 min at room temperature. To the reaction mixture, cyclohexyl chloroformate (2.0 ml) was added in one portion at 0° C. After stirring of the mixture for 1 hour at room temperature, pyridine was evaporated under reduced pressure. The residue was then partitioned between saturated aqueous NaHCO3 and ether. The organic layer was washed with brine, dried over anhydrous MgSO4 and concentrated under reduced pressure. To the residue were added citric acid (2.0 g) and methanol (50 ml). The mixture was stirred at room temperature overnight. After removal of the solvent under reduced pressure, the residue was dissolved in CH2 Cl2 /MeOH (95:5) and neutralized by aqueous NaOH. The organic layer was dried over anhydrous Na2 SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography using CH2 Cl2 /MeOH (20:1) as an eluent, followed by recrystallization from ethyl acetate to give N4 -(cyclohexyloxycarbonyl)-5'-deoxy-5-fluorocytidine (3.47 g:92% yield):mp. 134°-136° C., FAB-MS m/z 372 (MH+).
The following compounds were obtained according to a manner analogous to that of Example 19.
______________________________________
Ex-
am- Recrystall-
ple Melting ization FAB-MS
No. R.sup.1 R.sup.2
point (°C.)
solvent m/z
______________________________________
20 2- H 128-129.5
AcOEt 400(MH.sup.+)
cyclohexyl-
ethyl
21 3- H amorphous*
-- 414(MH.sup.+)
cyclohexyl-
propyl
22 3-phenyl- H 120-121 AcOEt 408(MH.sup.+)
propyl
23 2-methoxy- H amorphous*
-- 348(MH.sup.+)
ethyl *
24 isobutyl H 132-134 AcOEt 346(MH.sup.+)
25 2- H 116-118 AcOEt 402(MH.sup.+)
propylpentyl
26 2- H amorphous*
-- 402(MH.sup.+)
ethylhexyl **
27 n-heptyl H 115.5-117.5
AcOEt 388(MH.sup.+)
______________________________________
*.sup.1 HNMR(d.sub.6DMSO) of Example 21:
δ 0.78-0.93(2H, m), 1.15-1.27(6H, m), 1.31(3H, d, J=7Hz),
1.59-1.75(7H, m), 3.68(1H, q, J=6Hz), 3.89(1H, br. t, J=6Hz),
4.01-4.14(3H, m), 5.04(1H, d, J=6Hz), 5.40(1H, d, J=6Hz), 5.67(1H, d,
J=2Hz), 8.00(1H, br. s), 10.03 & 10.53(total 1H, br. s each).
**.sup.2 HNMR(d.sub.6DMSO) of Example 23:
δ 1.31(3H, d, J=5.9Hz), 3.28(3H, s), 3.56(2H, br. t), 3.69(1H, t,
J=6Hz), 3.89(1H, m), 4.06(1H, m), 4.22(2H, br. t), 5.05(1H, d, J=6Hz),
5.40(1H, br. s), 5.67(1H, d, J=3Hz), 8.06(1H, br. s), 10.65(1H, br. s).
***.sup.1 HNMR(d.sub.6DMSO) of Example 26:
δ 0.85-0.88(6H, m), 1.27-1.38(11H, m), 1.57(1H, br. d, J=6Hz),
3.68(1H, q, J=6Hz), 3.89-4.02(4H, m), 5.05(1H, br. s), 5.41(1H, br. s),
5.67(1H, d, J=3Hz), 8.06(1H, br. s), 10.52(1H, br. s).
Preparation of 5'-deoxy-5-fluoro-N4 -(neopentyloxycarbonyl)cytidine
5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine (1.5 g) and dry pyridine (0.74 ml) were dissolved in dry dichloromethane (15 ml). To the mixture, toluene solution of neopentyl chloroformate (3 eq.) was added dropwise at 0° C., and stirred at room temperature for 1 hour. After the solvent was removed under reduced pressure, the residue was partitioned between ether and saturated aqueous solution of sodium carbonate. The organic layer was successively washed with water and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give crude 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 (neopentyloxycarbonyl)cytidine as pale yellow oil. This crude product was dissolved in ethanol (15 ml) and cooled on ice-bath. Then 1N aqueous sodium hydroxide solution was added dropwise while maintaining the temperature below 15° C. After the addition was completed, the reaction mixture was neutralized with concentrated. hydrochloric acid at 0° C. The solution was concentrated under reduced pressure, and the concentrate was partitioned between water and a mixed solution of CH2 Cl.sub. 2 /MeOH (95:5). The aqueous layer was back-extracted with CH2 Cl2 /MeOH (95:5) ten times (20 ml each). All organic layers were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using CH2 Cl2 /MeOH (20:1) as an eluent to give 5'-deoxy-5-fluoro-N4 -(neopentyloxycarbonyl)cytidine (1.37 g: 84% yield) as amorphous powder: FAB-MS m/z 360 (MH+); 1 H-NMR (d6 -DMSO) δ0.93 (9H, s), 1.31 (3H, d,J=6.3 Hz), 3.68 (1H,q,J=5.9 Hz), 3.81 (2H, br. s), 3.87-3.92 (1H, m), 4.04-4.09 (1H, m), 5.05 (1H,d,J=5.9 Hz), 5.41 (1H, br. d, J=5.3 Hz), 5.67 (1H,dd,J=1.3, 3.6 Hz), 8.04 (1H, br. s), 10.53 (˜1H, br. s).
Preparation of 5'-Deoxy-N4 -[(3,3-dimethylbutoxy)carbonyl]-5-fluorocytidine
5'-Deoxy-N4 -[(3,3-dimethylbutoxy)carbonyl]-5-fluorocytidine was obtained according to a manner analogous to that of Example 28 except that 3,3-dimethylbutyl chloroformate was used as the acylating agent:amorphous powder (71% yield); FAB-MS m/z 374 (MH+); 1 H-NMR (d6 -DMSO) δ0.93 (9H, s), 1.31 (3H,d,J=6.3 Hz), 1.55 (2H,t,J=7.3 Hz), 3.68 (1H,q,J=5.9 Hz), 3.84-3.93 (1H, m), 4.03-4.09 (1H, m), 4.15 (2H,t,J=7.3 Hz), 5.05 (1H,d,J=5.9 Hz), 5.40 (1H, br, d,J=5.3 Hz), 5.67 (1H,dd,J=1.3, 4.0 Hz), 8.00 (1H, br. s), 10.53 (˜1H, br. s).
The following examples illustrate pharmaceutical preparations containing a compound provided by the present invention.
Interlocking gelatin capsules each containing the following ingredients were manufactured in a manner known per se:
______________________________________
N.sup.4 -(Butoxycarbonyl)-5'-deoxy-5-fluorocytidine
100 mg
Corn starch 20 mg
Titanium dioxide 385 mg
Magnesium stearate 5 mg
Film 20 mg
PEG 6000 3 mg
Talc 10 mg
543 mg
______________________________________
Tablets each containing the following ingredients were manufactured in a manner known per se:
______________________________________
N.sup.4 -(Butoxycarbonyl)-5'-deoxy-5-fluorocytidine
100 mg
Lactose 25 mg
Corn starch 20.2 mg
Hydroxypropylmethyl cellulose
4 mg
Magnesium stearate 0.8 mg
Film 10 mg
PEG 6000 1.5 mg
Talc 4.5 mg
166 mg
______________________________________
Dry parenteral dosage forms were manufactured in a manner known per se:
(1) A total 5 g of N4 -(butoxycarbonyl)-5'-deoxy-5-fluorocytidine was dissolved in 75 ml of distilled water, the solution was subjected to a bacteriological filtration, and then divided aseptically into 10 sterile vials. The solution was then freeze-dried to yield 500 mg of sterile dry solid per vial.
(2) Clean N4 -(butoxycarbonyl)-5'-deoxy-5-fluorocytidine in the amount of 500 mg per vial or ampoule was sealed in the receptacle and heat-sterilized.
The above dry dosage forms were reconstituted before use by adding a suitable sterile aqueous solvent such as water for injection or isotonic sodium chloride or 5% dextrose for parenteral administration.
Claims (6)
1. A compound of formula (I), ##STR6## wherein R1 is a saturated straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH2)n--Y wherein Y is a cyclohexyl radical, a C1 -C4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4, and when Y is C1 -C4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,
or a hydrate or solvate thereof.
2. The compounds according to claim 1, wherein R1 is selected from the group consisting of n-propyl, 1-isopropyl-2-methylpropyl, 1,1,2-trimethylpropyl, n-butyl, isobutyl, 2-ethylbutyl, 3,3-dimethylbutyl, n-pentyl, isopentyl, neopentyl, 2-propylpentyl, n-hexyl, 2-ethylhexyl, n-hetpyl, cyclohexyl, cyclohexylbutyl, 2-methoxyethyl, 2-ethoxyethyl, 3-methoxypropyl, 3-ethoxypropyl, 4-methoxybutyl, 4-ethoxybutyl, phenethyl, 3-phenyl-propyl and 4-phenylbutyl.
3. The compounds according to claim 1, selected from a group consisting of:
5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -(hexyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -(isopentyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -(neopentyloxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -[(1,1,2-trimethylpropoxy)carbonyl]cytidine,
5'-deoxy-N4 -[(3,3-dimethylbutoxy)carbonyl]-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -[(1-isopropyl-2-methylpropoxy)carbonyl]cytidine,
5'-deoxy-N4 -[(2-ethylbutyl)oxycarbonyl]-5-fluorocytidine,
N4 -[(cyclohexylmethoxy)carbonyl]-5'-deoxy-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -[(2-phenylethoxy)carbonyl]cytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(propoxycarbonyl)cytidine,
2',3'-di-O-acetyl-N4 -(butoxycarbonyl)-5'-deoxy-5-fluorocytidine,
2',3'-di-O-benzoyl-N4 -(butoxycarbonyl)-5 '-deoxy-5-fluorocytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(pentyloxycarbonyl)cytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(isopentyloxycarbonyl)cytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -(hexyloxycarbonyl)cytidine,
2',3'-di-O-acetyl-5'-deoxy-N4 -[(2-ethylbutyl)oxycarbonyl]-5-fluorocytidine,
2',3'-di-O-acetyl-N4 -[(cyclohexylmethoxy)carbonyl]-5'-deoxy-5-fluorocytidine,
2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4 -[(2-phenylethoxy)carbonyl]cytidine,
5'-deoxy-5-fluoro-N4 -(isobutoxycarbonyl)cytidine,
5'-deoxy-5-fluoro-N4 -[(2-propylpentyl)oxycarbonyl]cytidine,
' -deoxy-N4 -[(2-ethylhexyl)oxycarbonyl]-5'-fluorocytidine,
5'-deoxy-5-fluoro-N4 -(heptyloxycarbonyl)cytidine,
N4 -[(2-cyclohexylethoxy)carbonyl]-5'-deoxy-5-fluorocytidine,
N4 -[(3-cyclohexylpropyl)oxycarbonyl]-5'-deoxy-5-fluorocytidine,
N4 -(cyclohexyloxycarbonyl)-5'-deoxy-5-fluorocytidine,
5'-deoxy-5-fluoro-N4 -[(3-phenylpropyl)oxycarbonyl]cytidine,
5'-deoxy-5-fluoro-N4 -[(2-methoxyethoxy)carbonyl]cytidine,
N4 -(butoxycarbonyl)-5'-deoxy-5-fluorocytidine and
5'-deoxy-5-fluoro-N4 -(pentyloxycarbonyl)cytidine.
4. A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of formula (I) ##STR7## wherein R1 is a saturated straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of the hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH2)n --Y wherein Y is a cyclohexyl radical, a C1 -C4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4 and when Y is a C1 -C4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,
or a hydrate or solvate thereof, and an inert carrier.
5. A method of treating tumors comprising administering to a host in need of such treatment an effective amount of a compound of formula (I) ##STR8## wherein R1 is a saturated straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of the hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH2)n --Y wherein Y is a cyclohexyl radical, a C1 -C4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4 and when Y is a C1 -C4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,
or a hydrate or solvate thereof.
6. The compound according to claim 1, 5'-deoxy-5-fluoro-N4 -(pentyloxycarbonyl)cytidine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92121538 | 1992-12-18 | ||
| EP92121538 | 1992-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5472949A true US5472949A (en) | 1995-12-05 |
Family
ID=8210304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US08/167,392 Expired - Lifetime US5472949A (en) | 1992-12-18 | 1993-12-14 | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same |
Country Status (41)
| Country | Link |
|---|---|
| US (1) | US5472949A (en) |
| EP (1) | EP0602454B1 (en) |
| JP (1) | JP2501297B2 (en) |
| KR (1) | KR100347218B1 (en) |
| CN (1) | CN1035617C (en) |
| AT (1) | ATE137244T1 (en) |
| AU (1) | AU671491B2 (en) |
| BG (1) | BG61485B1 (en) |
| BR (1) | BR9305089A (en) |
| CA (1) | CA2103324C (en) |
| CZ (1) | CZ284788B6 (en) |
| DE (1) | DE69302360T2 (en) |
| DK (1) | DK0602454T3 (en) |
| EE (1) | EE03086B1 (en) |
| ES (1) | ES2086856T3 (en) |
| FI (1) | FI112365B (en) |
| GE (1) | GEP20074251B (en) |
| GR (1) | GR3020286T3 (en) |
| HK (1) | HK1005875A1 (en) |
| HR (1) | HRP931430B1 (en) |
| HU (2) | HU218291B (en) |
| IL (1) | IL108000A0 (en) |
| IS (1) | IS4108A (en) |
| LT (1) | LT3115B (en) |
| LV (1) | LV10625B (en) |
| MY (1) | MY109282A (en) |
| NO (1) | NO300066B1 (en) |
| NZ (1) | NZ250414A (en) |
| PH (1) | PH30168A (en) |
| PL (1) | PL174100B1 (en) |
| RO (1) | RO112619B1 (en) |
| RU (2) | RU2493162C1 (en) |
| SA (1) | SA93140409B1 (en) |
| SI (1) | SI9300648B (en) |
| SK (1) | SK281403B6 (en) |
| SV (1) | SV1993000080A (en) |
| TW (1) | TW372239B (en) |
| UA (1) | UA39158C2 (en) |
| UY (1) | UY23697A1 (en) |
| YU (1) | YU49411B (en) |
| ZA (1) | ZA939293B (en) |
Cited By (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2325931A (en) * | 1997-06-02 | 1998-12-09 | Hoffmann La Roche | 5'-Deoxy Cytidine Derivatives |
| US6005098A (en) * | 1998-02-06 | 1999-12-21 | Hoffmann-La Roche Inc. | 5'deoxycytidine derivatives |
| US6503889B2 (en) * | 2000-02-28 | 2003-01-07 | Aventis Pharma S.A. | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| US20030170300A1 (en) * | 1998-09-25 | 2003-09-11 | Grove William Richard | Combination chemotherapy |
| WO2004045617A1 (en) * | 2002-11-15 | 2004-06-03 | Warner-Lambert Company Llc | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| WO2005049031A1 (en) * | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Combination |
| US20050137392A1 (en) * | 2003-12-22 | 2005-06-23 | Roche Colorado Corporation | Process for producing N4-Acyl-5'-deoxy-5-fluorocytidine |
| US20060089327A1 (en) * | 2002-01-14 | 2006-04-27 | Hohneker John A | Combinations comprising epothilones and anti-metabolites |
| US20060223780A1 (en) * | 2005-04-01 | 2006-10-05 | Ute Dugan | Method for administration of capecitabine |
| US20070122481A1 (en) * | 1998-11-02 | 2007-05-31 | Elan Corporation Plc | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer |
| KR100730768B1 (en) * | 2000-08-09 | 2007-06-21 | 코오롱생명과학 주식회사 | 5'-deoxy-N-alkyloxycarbonyl-5-fluorocytosine-5'-carboxylic acid and its derivatives, and process for preparing thereof |
| US20080026044A1 (en) * | 2003-05-20 | 2008-01-31 | Jonathan Lewis | Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex |
| US20080085310A1 (en) * | 2006-10-06 | 2008-04-10 | Maria Oksana Bachynsky | Capecitabine rapidly disintegrating tablets |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| WO2008107771A2 (en) | 2007-03-05 | 2008-09-12 | Innovate Biotechnology S.R.L. | 2',3'-di-o-acyl-5-fluoronucleosides |
| CN100425617C (en) * | 2006-10-31 | 2008-10-15 | 浙江海正药业股份有限公司 | Fluoropyrimidine compound carbalkoxylation method |
| US20080300399A1 (en) * | 2007-06-01 | 2008-12-04 | Ettema Gerrit J B | Processes related to making capecitabine |
| US20090075931A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched capecitabine |
| WO2009071726A1 (en) | 2007-12-06 | 2009-06-11 | Coll Farma S.L. | Method for the preparation of capecitabine and intermediates used in said method |
| WO2009088989A1 (en) * | 2008-01-03 | 2009-07-16 | Plus Chemicals, S.A. | Process for the preparation of capecitabine |
| US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
| US20100113474A1 (en) * | 2008-08-04 | 2010-05-06 | Wyeth | Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine |
| US20100130734A1 (en) * | 2007-04-20 | 2010-05-27 | Dr. Reddy's Laboratories Ltd. | Process for preparing capecitabine |
| WO2010063080A1 (en) | 2008-12-05 | 2010-06-10 | Commonwealth Scientific And Industrial Research Organisation | Amphiphile prodrugs |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| US20100249395A1 (en) * | 2007-11-19 | 2010-09-30 | Hanmi Pharm. Co., Ltd. | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein |
| WO2010128258A1 (en) | 2009-05-06 | 2010-11-11 | Sanofi-Aventis | Antitumor combination including cabazitaxel and capecitabine |
| US20100286084A1 (en) * | 2007-09-21 | 2010-11-11 | Nektar Therapeutics | Oligomer-Nucleoside Phosphate Conjugates |
| WO2010065586A3 (en) * | 2008-12-02 | 2010-11-18 | Dr. Reddy's Laboratories Ltd. | Preparation of capecitabine |
| EP2266590A2 (en) | 2002-02-22 | 2010-12-29 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
| WO2011067588A1 (en) | 2009-12-04 | 2011-06-09 | Generics [Uk] Limited | Cyclic sulphinyl esters of cytidine |
| WO2011104540A1 (en) | 2010-02-24 | 2011-09-01 | Generics [Uk] Limited | One step process for the preparation of capecitabine |
| CN102266303A (en) * | 2011-07-07 | 2011-12-07 | 程雪翔 | Capecitabine medicinal composition and preparation method thereof |
| EP2428213A1 (en) | 2005-07-21 | 2012-03-14 | Nuvo Research AG | Stabilized chlorite solutions in combination with fluoropyrimidines for use in cancer treatment |
| CN102558262A (en) * | 2010-12-23 | 2012-07-11 | 天津泰普药品科技发展有限公司 | Preparation method of high-purity capecitabine |
| US8377985B2 (en) | 2005-07-18 | 2013-02-19 | Bipar Sciences, Inc. | Treatment of cancer |
| US20130184451A1 (en) * | 2012-01-13 | 2013-07-18 | Pharmaessentia Corp. | Novel synthesis of 5-deoxy-5'-fluorocytidine compounds |
| EP2835053A1 (en) | 2010-03-12 | 2015-02-11 | Genzyme Corporation | Combination therapy for treating breast cancer |
| US20150065447A1 (en) * | 2013-08-20 | 2015-03-05 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| US9139558B2 (en) | 2007-10-17 | 2015-09-22 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US9211291B2 (en) | 2009-04-06 | 2015-12-15 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| WO2015191576A1 (en) | 2014-06-09 | 2015-12-17 | Lipomedix Pharmaceuticals Ltd. | Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy |
| US9511063B2 (en) | 2008-06-17 | 2016-12-06 | Wyeth Llc | Antineoplastic combinations containing HKI-272 and vinorelbine |
| US9623029B2 (en) | 2009-05-22 | 2017-04-18 | Incyte Holdings Corporation | 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors |
| US9662335B2 (en) | 2005-12-13 | 2017-05-30 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
| US9714233B2 (en) | 2013-03-06 | 2017-07-25 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
| US9718834B2 (en) | 2011-09-07 | 2017-08-01 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
| US9999619B2 (en) | 2010-03-10 | 2018-06-19 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| US10342790B2 (en) * | 2017-02-20 | 2019-07-09 | Anadolu Universitesi Rektorlugu | Use of ceranib-2 in the treatment of lung cancer |
| WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US10513522B2 (en) | 2011-06-20 | 2019-12-24 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| US10561616B2 (en) | 2013-08-07 | 2020-02-18 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US10596162B2 (en) | 2005-02-03 | 2020-03-24 | Wyeth Llc | Method for treating gefitinib resistant cancer |
| US10640506B2 (en) | 2010-11-19 | 2020-05-05 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors |
| WO2020144657A1 (en) | 2019-01-11 | 2020-07-16 | Lipomedix Pharmaceuticals Ltd. | Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture |
| US10729672B2 (en) | 2005-11-04 | 2020-08-04 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272 |
| US10758543B2 (en) | 2010-05-21 | 2020-09-01 | Incyte Corporation | Topical formulation for a JAK inhibitor |
| US10899736B2 (en) | 2018-01-30 | 2021-01-26 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
| US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US11213528B2 (en) | 2007-06-13 | 2022-01-04 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
| US11337927B2 (en) | 2012-11-15 | 2022-05-24 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| WO2023177894A1 (en) | 2022-03-18 | 2023-09-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476932A (en) * | 1994-08-26 | 1995-12-19 | Hoffmann-La Roche Inc. | Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives |
| EP0882734B1 (en) * | 1997-06-02 | 2009-08-26 | F. Hoffmann-La Roche Ag | 5'-Deoxy-cytidine derivatives |
| WO2001076581A1 (en) * | 2000-04-11 | 2001-10-18 | Sayuri Yamada | Curcumin compositions |
| KR100631754B1 (en) * | 2000-08-09 | 2006-10-09 | 주식회사 코오롱 | N-alkyloxycarbonyl-5-fluorocytosine derivatives and preparation method thereof |
| GB0113374D0 (en) * | 2001-06-04 | 2001-07-25 | Jerram Clare | Washing line umbrella |
| US20110021769A1 (en) * | 2009-07-23 | 2011-01-27 | Scinopharm Taiwan Ltd. | Process for Producing Fluorocytidine Derivatives |
| CN102260309B (en) * | 2010-05-24 | 2014-10-22 | 重庆福安药业(集团)股份有限公司 | Method for preparing high-purity capecitabine |
| CN102516338B (en) * | 2011-12-09 | 2014-04-02 | 海南锦瑞制药股份有限公司 | Capecitabine compound, pharmaceutical composition and preparation method thereof |
| EP2883959A1 (en) | 2013-12-13 | 2015-06-17 | Plasmia Biotech, S.L. | Enzymatic production of cytosinic nucleoside analogues |
| CN103897006A (en) * | 2013-12-18 | 2014-07-02 | 吉林修正药业新药开发有限公司 | Preparation method of capecitabine isomer |
| CN104530164A (en) * | 2014-12-31 | 2015-04-22 | 辰欣药业股份有限公司 | Synthesis technology for capecitabine |
| KR20160117060A (en) | 2015-03-31 | 2016-10-10 | 이승주 | Baby table |
| CN105646625B (en) * | 2015-12-29 | 2019-06-11 | 江苏吴中医药集团有限公司 | A kind of preparation method of capecitabine |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| CN111801339A (en) * | 2018-01-19 | 2020-10-20 | 纽科利制药公司 | 5-fluorouracil compounds |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| EP4143199A1 (en) | 2020-04-21 | 2023-03-08 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4966891A (en) * | 1987-11-17 | 1990-10-30 | Hoffmann-La Roche Inc. | Fluorocytidine derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1135258A (en) * | 1979-06-15 | 1982-11-09 | Richard D'souza | Process for the preparation of 5'deoxy-5-fluorouridine |
| CA1264738A (en) * | 1984-12-04 | 1990-01-23 | Eli Lilly And Company | Treatment of tumors in mammals |
-
1993
- 1993-11-12 AU AU50690/93A patent/AU671491B2/en not_active Expired
- 1993-11-15 TW TW082109533A patent/TW372239B/en not_active IP Right Cessation
- 1993-11-17 CA CA002103324A patent/CA2103324C/en not_active Expired - Lifetime
- 1993-11-23 HR HR92121538.0A patent/HRP931430B1/en not_active IP Right Cessation
- 1993-12-01 ES ES93119349T patent/ES2086856T3/en not_active Expired - Lifetime
- 1993-12-01 AT AT93119349T patent/ATE137244T1/en active
- 1993-12-01 EP EP93119349A patent/EP0602454B1/en not_active Expired - Lifetime
- 1993-12-01 DK DK93119349.4T patent/DK0602454T3/en active
- 1993-12-01 DE DE69302360T patent/DE69302360T2/en not_active Expired - Lifetime
- 1993-12-07 SA SA93140409A patent/SA93140409B1/en unknown
- 1993-12-10 SI SI9300648A patent/SI9300648B/en unknown
- 1993-12-10 HU HU9303525A patent/HU218291B/en active Protection Beyond IP Right Term
- 1993-12-10 ZA ZA939293A patent/ZA939293B/en unknown
- 1993-12-10 NZ NZ250414A patent/NZ250414A/en not_active IP Right Cessation
- 1993-12-13 CZ CZ932731A patent/CZ284788B6/en not_active IP Right Cessation
- 1993-12-13 IL IL10800093A patent/IL108000A0/en not_active IP Right Cessation
- 1993-12-14 FI FI935616A patent/FI112365B/en not_active IP Right Cessation
- 1993-12-14 US US08/167,392 patent/US5472949A/en not_active Expired - Lifetime
- 1993-12-15 PH PH47455A patent/PH30168A/en unknown
- 1993-12-15 YU YU77993A patent/YU49411B/en unknown
- 1993-12-15 RO RO93-01706A patent/RO112619B1/en unknown
- 1993-12-16 RU RU2012134029/04A patent/RU2493162C1/en not_active IP Right Cessation
- 1993-12-16 JP JP5342812A patent/JP2501297B2/en not_active Expired - Fee Related
- 1993-12-16 MY MYPI93002726A patent/MY109282A/en unknown
- 1993-12-16 RU RU93056196/04A patent/RU2458932C2/en active Protection Beyond IP Right Term
- 1993-12-16 BG BG98304A patent/BG61485B1/en unknown
- 1993-12-16 KR KR1019930027962A patent/KR100347218B1/en not_active IP Right Cessation
- 1993-12-16 BR BR9305089A patent/BR9305089A/en not_active Application Discontinuation
- 1993-12-17 SK SK1444-93A patent/SK281403B6/en not_active IP Right Cessation
- 1993-12-17 SV SV1993000080A patent/SV1993000080A/en not_active Application Discontinuation
- 1993-12-17 LT LTIP1627A patent/LT3115B/en not_active IP Right Cessation
- 1993-12-17 LV LVP-93-1347A patent/LV10625B/en unknown
- 1993-12-17 IS IS4108A patent/IS4108A/en unknown
- 1993-12-17 NO NO934671A patent/NO300066B1/en not_active IP Right Cessation
- 1993-12-17 UA UA93004687A patent/UA39158C2/en unknown
- 1993-12-17 CN CN93112838A patent/CN1035617C/en not_active Expired - Lifetime
- 1993-12-17 UY UY23697A patent/UY23697A1/en not_active IP Right Cessation
- 1993-12-17 PL PL93301541A patent/PL174100B1/en unknown
-
1994
- 1994-11-18 EE EE9400154A patent/EE03086B1/en not_active IP Right Cessation
-
1995
- 1995-06-19 HU HU95P/P00255P patent/HU211965A9/en unknown
-
1996
- 1996-06-19 GR GR960401668T patent/GR3020286T3/en unknown
-
1998
- 1998-06-05 HK HK98105008A patent/HK1005875A1/en not_active IP Right Cessation
-
2006
- 2006-07-17 GE GEAP20069525A patent/GEP20074251B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4966891A (en) * | 1987-11-17 | 1990-10-30 | Hoffmann-La Roche Inc. | Fluorocytidine derivatives |
Non-Patent Citations (2)
| Title |
|---|
| Umeda et al., "Synthesis and antitumor activity of 5'-deoxy-5-fluorocytidine (5'-DFCR) derivatives", J. Pharmacobio-Dyn., 13:s-144 (1990). |
| Umeda et al., Synthesis and antitumor activity of 5 deoxy 5 fluorocytidine (5 DFCR) derivatives , J. Pharmacobio Dyn., 13:s 144 (1990). * |
Cited By (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2325931A (en) * | 1997-06-02 | 1998-12-09 | Hoffmann La Roche | 5'-Deoxy Cytidine Derivatives |
| US6114520A (en) * | 1997-06-02 | 2000-09-05 | Hoffmann-La Roche Inc. | 5'-deoxy-cytidine derivatives |
| US6211166B1 (en) * | 1997-06-02 | 2001-04-03 | Hoffman-La Roche Inc. | 5′-deoxy-cytidine derivative administration to treat solid tumors |
| GB2325931B (en) * | 1997-06-02 | 2001-07-25 | Hoffmann La Roche | 5'-Deoxy-cytidine compounds and their use as anti-tumor agents |
| US6005098A (en) * | 1998-02-06 | 1999-12-21 | Hoffmann-La Roche Inc. | 5'deoxycytidine derivatives |
| US20030170300A1 (en) * | 1998-09-25 | 2003-09-11 | Grove William Richard | Combination chemotherapy |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| US20070122481A1 (en) * | 1998-11-02 | 2007-05-31 | Elan Corporation Plc | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer |
| US6503889B2 (en) * | 2000-02-28 | 2003-01-07 | Aventis Pharma S.A. | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| US20030096789A1 (en) * | 2000-02-28 | 2003-05-22 | Aventis Pharma S.A. | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| US6664242B2 (en) | 2000-02-28 | 2003-12-16 | Aventis Pharma S.A. | Composition and method comprising CPT-11 and a pyrimidine derivative for the treatment of cancer |
| KR100730768B1 (en) * | 2000-08-09 | 2007-06-21 | 코오롱생명과학 주식회사 | 5'-deoxy-N-alkyloxycarbonyl-5-fluorocytosine-5'-carboxylic acid and its derivatives, and process for preparing thereof |
| US20060089327A1 (en) * | 2002-01-14 | 2006-04-27 | Hohneker John A | Combinations comprising epothilones and anti-metabolites |
| EP2030618A2 (en) | 2002-01-14 | 2009-03-04 | Novartis AG | Combinations comprising epothilones and anti-metabolites |
| US20090298791A1 (en) * | 2002-01-14 | 2009-12-03 | John Arthur Hohneker | Combinations comprising epothilones and antimetabolites |
| US20110082101A1 (en) * | 2002-01-14 | 2011-04-07 | John Arthur Hohneker | Combinations comprising epothilones and anti-metabolites |
| EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| EP2266590A2 (en) | 2002-02-22 | 2010-12-29 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
| EP2316469A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| WO2004045617A1 (en) * | 2002-11-15 | 2004-06-03 | Warner-Lambert Company Llc | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| US20080026044A1 (en) * | 2003-05-20 | 2008-01-31 | Jonathan Lewis | Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex |
| US20070190164A1 (en) * | 2003-11-13 | 2007-08-16 | Pharma Mar, S.A.U. | Combination |
| US7622458B2 (en) | 2003-11-13 | 2009-11-24 | Pharma Mar, S.A.U. | Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment |
| WO2005049031A1 (en) * | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Combination |
| US7365188B2 (en) * | 2003-12-22 | 2008-04-29 | Roche Colorado Corporation | Process for producing N4-Acyl-5′-deoxy-5-fluorocytidine |
| US20050137392A1 (en) * | 2003-12-22 | 2005-06-23 | Roche Colorado Corporation | Process for producing N4-Acyl-5'-deoxy-5-fluorocytidine |
| US10596162B2 (en) | 2005-02-03 | 2020-03-24 | Wyeth Llc | Method for treating gefitinib resistant cancer |
| US10603314B2 (en) | 2005-02-03 | 2020-03-31 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| JP2008534548A (en) * | 2005-04-01 | 2008-08-28 | エフ．ホフマン−ラ ロシュ アーゲー | Methods for administration of capecitabine |
| US20060223780A1 (en) * | 2005-04-01 | 2006-10-05 | Ute Dugan | Method for administration of capecitabine |
| US8377985B2 (en) | 2005-07-18 | 2013-02-19 | Bipar Sciences, Inc. | Treatment of cancer |
| EP2428213A1 (en) | 2005-07-21 | 2012-03-14 | Nuvo Research AG | Stabilized chlorite solutions in combination with fluoropyrimidines for use in cancer treatment |
| US10729672B2 (en) | 2005-11-04 | 2020-08-04 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272 |
| US11331320B2 (en) | 2005-12-13 | 2022-05-17 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US9814722B2 (en) | 2005-12-13 | 2017-11-14 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
| US10398699B2 (en) | 2005-12-13 | 2019-09-03 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| US9974790B2 (en) | 2005-12-13 | 2018-05-22 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
| US10639310B2 (en) | 2005-12-13 | 2020-05-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US9662335B2 (en) | 2005-12-13 | 2017-05-30 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
| US11744832B2 (en) | 2005-12-13 | 2023-09-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| US20080085310A1 (en) * | 2006-10-06 | 2008-04-10 | Maria Oksana Bachynsky | Capecitabine rapidly disintegrating tablets |
| CN100425617C (en) * | 2006-10-31 | 2008-10-15 | 浙江海正药业股份有限公司 | Fluoropyrimidine compound carbalkoxylation method |
| WO2008107771A2 (en) | 2007-03-05 | 2008-09-12 | Innovate Biotechnology S.R.L. | 2',3'-di-o-acyl-5-fluoronucleosides |
| US20100130734A1 (en) * | 2007-04-20 | 2010-05-27 | Dr. Reddy's Laboratories Ltd. | Process for preparing capecitabine |
| US20080300399A1 (en) * | 2007-06-01 | 2008-12-04 | Ettema Gerrit J B | Processes related to making capecitabine |
| US11213528B2 (en) | 2007-06-13 | 2022-01-04 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| US20110039872A1 (en) * | 2007-09-15 | 2011-02-17 | Protia, Llc | Deuterium-enriched capecitabine |
| US20090075931A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched capecitabine |
| US7842675B2 (en) | 2007-09-15 | 2010-11-30 | Protia, Llc | Deuterium-enriched capecitabine |
| US20100286084A1 (en) * | 2007-09-21 | 2010-11-11 | Nektar Therapeutics | Oligomer-Nucleoside Phosphate Conjugates |
| US9365604B2 (en) | 2007-09-21 | 2016-06-14 | Nektar Therapeutics | Oligomer-nucleoside phosphate conjugates |
| US8741858B2 (en) * | 2007-09-21 | 2014-06-03 | Zhongxu Ren | Oligomer-nucleoside phosphate conjugates |
| US9630946B2 (en) | 2007-10-17 | 2017-04-25 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US9139558B2 (en) | 2007-10-17 | 2015-09-22 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US10035788B2 (en) | 2007-10-17 | 2018-07-31 | Wyeth Llc | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US20100249395A1 (en) * | 2007-11-19 | 2010-09-30 | Hanmi Pharm. Co., Ltd. | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein |
| US8097706B2 (en) | 2007-11-19 | 2012-01-17 | Hammi Holdings Co., Ltd | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein |
| WO2009071726A1 (en) | 2007-12-06 | 2009-06-11 | Coll Farma S.L. | Method for the preparation of capecitabine and intermediates used in said method |
| WO2009088989A1 (en) * | 2008-01-03 | 2009-07-16 | Plus Chemicals, S.A. | Process for the preparation of capecitabine |
| US20090209754A1 (en) * | 2008-01-03 | 2009-08-20 | Macdonald Peter Lindsay | Process for the preparation of capecitabine |
| US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
| US10111868B2 (en) | 2008-06-17 | 2018-10-30 | Wyeth Llc | Antineoplastic combinations containing HKI-272 and vinorelbine |
| US9511063B2 (en) | 2008-06-17 | 2016-12-06 | Wyeth Llc | Antineoplastic combinations containing HKI-272 and vinorelbine |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| US20100113474A1 (en) * | 2008-08-04 | 2010-05-06 | Wyeth | Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine |
| US9265784B2 (en) | 2008-08-04 | 2016-02-23 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| EP3175853A1 (en) | 2008-08-04 | 2017-06-07 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| US20110224422A1 (en) * | 2008-12-02 | 2011-09-15 | Dr. Reddy's Laboratories Ltd. | Preparation of capecitabine |
| WO2010065586A3 (en) * | 2008-12-02 | 2010-11-18 | Dr. Reddy's Laboratories Ltd. | Preparation of capecitabine |
| WO2010063080A1 (en) | 2008-12-05 | 2010-06-10 | Commonwealth Scientific And Industrial Research Organisation | Amphiphile prodrugs |
| EP2393472A4 (en) * | 2008-12-05 | 2015-04-29 | Commw Scient Ind Res Org | Amphiphile prodrugs |
| US8603999B2 (en) | 2008-12-05 | 2013-12-10 | Commonwealth Scientific And Industrial Research Organisation | Amphiphile prodrugs |
| US9211291B2 (en) | 2009-04-06 | 2015-12-15 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| WO2010128258A1 (en) | 2009-05-06 | 2010-11-11 | Sanofi-Aventis | Antitumor combination including cabazitaxel and capecitabine |
| US9623029B2 (en) | 2009-05-22 | 2017-04-18 | Incyte Holdings Corporation | 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors |
| WO2011067588A1 (en) | 2009-12-04 | 2011-06-09 | Generics [Uk] Limited | Cyclic sulphinyl esters of cytidine |
| WO2011104540A1 (en) | 2010-02-24 | 2011-09-01 | Generics [Uk] Limited | One step process for the preparation of capecitabine |
| US10695337B2 (en) | 2010-03-10 | 2020-06-30 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| US11285140B2 (en) | 2010-03-10 | 2022-03-29 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| US9999619B2 (en) | 2010-03-10 | 2018-06-19 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| EP2835053A1 (en) | 2010-03-12 | 2015-02-11 | Genzyme Corporation | Combination therapy for treating breast cancer |
| EP3406141A1 (en) | 2010-03-12 | 2018-11-28 | Genzyme Corporation | Combination therapy for treating cancer |
| US11590136B2 (en) | 2010-05-21 | 2023-02-28 | Incyte Corporation | Topical formulation for a JAK inhibitor |
| US11571425B2 (en) | 2010-05-21 | 2023-02-07 | Incyte Corporation | Topical formulation for a JAK inhibitor |
| US11219624B2 (en) | 2010-05-21 | 2022-01-11 | Incyte Holdings Corporation | Topical formulation for a JAK inhibitor |
| US10758543B2 (en) | 2010-05-21 | 2020-09-01 | Incyte Corporation | Topical formulation for a JAK inhibitor |
| US10869870B2 (en) | 2010-05-21 | 2020-12-22 | Incyte Corporation | Topical formulation for a JAK inhibitor |
| US10640506B2 (en) | 2010-11-19 | 2020-05-05 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors |
| CN102558262A (en) * | 2010-12-23 | 2012-07-11 | 天津泰普药品科技发展有限公司 | Preparation method of high-purity capecitabine |
| US10513522B2 (en) | 2011-06-20 | 2019-12-24 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| US11214573B2 (en) | 2011-06-20 | 2022-01-04 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| CN102266303A (en) * | 2011-07-07 | 2011-12-07 | 程雪翔 | Capecitabine medicinal composition and preparation method thereof |
| US9718834B2 (en) | 2011-09-07 | 2017-08-01 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
| US8975393B2 (en) * | 2012-01-13 | 2015-03-10 | Pharmaessentia Corp. | Synthesis of 5-deoxy-5′-fluorocytidine compounds |
| US20130184451A1 (en) * | 2012-01-13 | 2013-07-18 | Pharmaessentia Corp. | Novel synthesis of 5-deoxy-5'-fluorocytidine compounds |
| US11896717B2 (en) | 2012-11-15 | 2024-02-13 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
| US11576865B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
| US11576864B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
| US11337927B2 (en) | 2012-11-15 | 2022-05-24 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
| US9714233B2 (en) | 2013-03-06 | 2017-07-25 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
| US10561616B2 (en) | 2013-08-07 | 2020-02-18 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
| US11045421B2 (en) | 2013-08-07 | 2021-06-29 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
| US20150065447A1 (en) * | 2013-08-20 | 2015-03-05 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| WO2015191576A1 (en) | 2014-06-09 | 2015-12-17 | Lipomedix Pharmaceuticals Ltd. | Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy |
| WO2015191563A1 (en) | 2014-06-09 | 2015-12-17 | Lipomedix Pharmaceuticals Ltd. | Combination chemotherapy comprising a liposomal prodrug of mitomycin c |
| EP4046989A1 (en) | 2017-01-09 | 2022-08-24 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US10342790B2 (en) * | 2017-02-20 | 2019-07-09 | Anadolu Universitesi Rektorlugu | Use of ceranib-2 in the treatment of lung cancer |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US11278541B2 (en) | 2017-12-08 | 2022-03-22 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| US10899736B2 (en) | 2018-01-30 | 2021-01-26 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
| US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
| WO2020144657A1 (en) | 2019-01-11 | 2020-07-16 | Lipomedix Pharmaceuticals Ltd. | Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2023177894A1 (en) | 2022-03-18 | 2023-09-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5472949A (en) | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same | |
| BRPI1100050A2 (en) | "Blade Tilt Control System, Wind Turbine Generator, and Blade Tilt Control Method". | |
| US4966891A (en) | Fluorocytidine derivatives | |
| JP3160288B2 (en) | Purine nucleosides | |
| EP0747389B1 (en) | 3'-substituted nucleoside derivatives | |
| US6114520A (en) | 5'-deoxy-cytidine derivatives | |
| EP0882734B1 (en) | 5'-Deoxy-cytidine derivatives | |
| US4946951A (en) | 2'-deoxy-5-fluorouridine derivatives | |
| US4992534A (en) | 3'-O-,5'-O-derivatives of 2'-deoxy-5-fluorouridine | |
| EP0450102A1 (en) | Nucleoside derivative | |
| HU179949B (en) | Process for preparing nitroso-carbamide derivatives | |
| US5283331A (en) | 2-halogeno-oxetanocin A and phosphoric ester thereof | |
| US5869464A (en) | 2'-Deoxy-5-fluorouridine derivatives, a process for their preparation, antitumor agents containing same and methods for using said agents | |
| JPWO2008010571A1 (en) | 2'-cyanopyrimidine nucleoside compounds | |
| KR870001935B1 (en) | Process for preparation of the antibiotic nucleoside and its salts | |
| KR100631754B1 (en) | N-alkyloxycarbonyl-5-fluorocytosine derivatives and preparation method thereof | |
| JPH10298194A (en) | 2-deoxy-3-ethynyl-beta-d-ribofuranosyl derivative | |
| KR20030017185A (en) | N4-alkyloxycarbonyl-5-fluorocytosine derivatives, method of preparing the same, and anticancer agent composition comprising the same | |
| JPH10330394A (en) | Hydroxyamino-substituted nucleoside derivative | |
| JPS6345644B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARASAKI, MOTOHIRO;ISHITSUKA, HIDEO;KURUMA, ISAMI;AND OTHERS;REEL/FRAME:006869/0383 Effective date: 19931227 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| AS | Assignment |
Owner name: HLR TECHNOLOGY CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOFFMANN-LA ROCHE INC.;REEL/FRAME:009958/0374 Effective date: 19990501 |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| AS | Assignment |
Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY Free format text: MERGER;ASSIGNOR:HLR TECHNOLOGY CORPORATION;REEL/FRAME:018679/0458 Effective date: 20030421 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |
|
| AS | Assignment |
Owner name: HOFFMANN-LA ROCHE, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:025952/0175 Effective date: 20110307 Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARASAKI, MOTOHIRO;ISHITSUKA, HIDEO;KURUMA, ISAMI;AND OTHERS;REEL/FRAME:025952/0731 Effective date: 19931018 |